FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:1012-1014 April 7, 1994 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Cannistra, S. A.

To the Editor: Dr. Cannistra stated in his review article on cancer of the ovary (Nov. 18 issue)¹ that "the regimen of cisplatin plus cyclophosphamide is just as effective as more complicated and toxic regimens, such as those containing altretamine or doxorubicin hydrochloride." It appears that the author did not review the literature critically. For example, Hainsworth et al. (Cannistra's reference 42) reported a response rate of 96 percent for the combination of altretamine (hexamethylmelamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP)². More important, the median survival for the entire group of patients was 45 months, and it was 72 months . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.